Efficacy and Safety of Turmeric in Active Rheumatoid Arthritis Patients Received Maximum Dose of DMARDS or DMARD-Intolerance

Main Article Content

อังคณา นรเศรษฐ์ธาดา

Abstract

Curcumin, an active ingredient of turmeric, is known potent anti-inflammatory and anti-rheumatic properties. Rheumatoid arthritis (RA) is a chronic destructive joint disease. Many patients with severe forms of the disease remain unresponsive to non-steroidal anti-inflammatory drugs and disease modifying anti-rheumatic drugs (DMARDS) or DMARD-intolerance. This study conducts a randomized control study to assess the efficacy and safety of turmeric compare with placebo in Buddhachinaraj Hospital Phitsanulok. Fifty active rheumatoid arthritis patients who take maximum dose of DMARDS or DMARD-intolerance were randomized into two groups with patients receiving turmeric (2gm/d) and placebo for 8 weeks. The primary endpoints were reduction in Disease activity score (DAS) 28. The secondary endpoints were American College of Rheumatology (ACR) criteria for reduction in tenderness and swelling of joint counts. Patients in turmeric group showed statistically significant reduction in their DAS28 and ACR scores (ACR20, 50 and 70). Turmeric treatment did not related with any adverse events. This study provides the safety and efficacy of turmeric treatment in refractory RA, and highlights the need for future large-scale trials to validate these findings

Keywords

Article Details

Section
Research Article
Author Biography

อังคณา นรเศรษฐ์ธาดา, Department of Internal Medicine, Buddhachinaraj Hospital, Phitsanulok



References

1. Chaiamnuay P, Darmawan J, Muirden KA, Assawatanabodee P, et al. Epidemiology of rheumatic disease in rural Thailand; a WHO-ILAR COPCORD Study. Community Oriented Programme for the Control of Rheumatic Disease. J Rheumatol 1998;25:1382-7.

2. Lacaille D, Hogg RS, The effect of arthritis on working life expectancy. J Rheumatol 2001;28:2315-9.

3. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.

4. Rasker JJ, Cosh JA. Course and prognosis of early rheumatoid arthritis. Scand J RheumatolSuppl1989;79:45-56.

5. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long term outcome of treating rheumatoid arthritis after 20 years. Lancet 1987;1:1108-11.

6. Aggarwal BB, Sandaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold.Adv Exp Med Biol 2007;595:1-75.

7. Goel A, Aggawal BB. Curcumin the golden spice from Indian saffron, is achemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-30.

8. Goel A, Boland CR, Chauhan DP.Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001;172:111-8.

9. Goel A, Jhurani S, Aggarwal BB. Multitargeted therapy by curcumin: how spicy is it? MolNutr Food Res 2008;52(9):1010-30.

10. Goel A, Kunnumakkara AB, Aggarwal BB. Curcuminas'Cure-cumin':from kitchen to clinic. BiochemPharmacol 2008b;75:787-809.

11. Bright JJ. Curcumin and autoimmune disease. AdvExp Med Biol2007;595:425-51.

12. Kamarudin TA, Othman F, MohdRamli ES, Md Isa N, Das S. Protective effect of curcumin on experimentally induced arthritic rats: detailed histopathological study of the joints and white blood cell count. EXCLI J 2012;11:226-36.

13. Hewlings SJ, Kalman DS. Curcumin: A review of its 'effects on Human Health. Foods2017;6(10):92.

14. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012;26(11):1719-25.

15. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas R. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med1988; 64(4):353-6.

16. Shen L, Liu C-C, An C-Y, Ji H-F. How dose curcumin work with poor bioavailability? Clue from experimental and theoretical studies.Sci Rep2016;6:20872-10.

17. DailyJW, YangM, Park S. Efficacy of Turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: A systematic review and meta-analysis of randomized clinical trials.J Med Food 2016;19(8):717-29.

18. Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis. J Altern Complement Med 2009;15(8):891-7.

19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24.

20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69(9):1580-8.

21. Van Gastel AM, Anderson JJ, van Riel PLCM, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR Improvement Criteria HaveComparable Validity in Rheumatoid Arthritis Trials. J Rheumatol1999;26:705-11.

22. Ngamjarus C, Chongsuvivatwong V.McNeil E. n4 Studies: Sample Size Calculation for an Epide-miological Study on a Smart Device. Siriraj Med J 2016;68:160-70.

23. Luqmani R. Getting Established on DMARD Therapy.National Rheumatoid Arthritis Society [serial on the internet].2006[cited 2019Sep19]. Available from URL:https://www.nras.org.uk/getting-established-ondmard-therapy